Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia (SMARTASIA)

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Asthma

Treatments: Drug: Symbicort (Budesonide/Formoterol)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00939341

D5890L00035

Details and patient eligibility

About

The purpose of this study is to compare whether Symbicort Maintenance & Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation.

Enrollment: 862 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of signed informed consent
• Asthma diagnosis at least 6 months before visit 1 of study
• Patients who have reversible airway obstruction continuous asthma treatment except Symbicort at least within 4 weeks before visit 1 of study

Exclusion criteria

• Known or suspected allergy to active ingredients of study medication or excipients
• Use of oral, rectal or parenteral glucocorticosteroids 30 days before visit 1 of study
• Smoking, current or previous with a smoking history of ≥ 10 pack years

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

862 participants in 1 patient group

1

Experimental group

Description:

Symbicort Turbuhaler 160/4.5 µg delivered dose

Treatment:

Drug: Symbicort (Budesonide/Formoterol)